Alsabti E
Med Pediatr Oncol. 1979;6(3):189-93. doi: 10.1002/mpo.2950060302.
Serum lysozyme activity was measured in samples from adult patients with acute leukemia, malignant tumors, and in normal adults. Twenty-eight adult patients with acute myelogenous leukemia (AML) had significantly elevated levels of lysozyme at diagnosis, and none of the adults fell within the normal range. Thirty-two patients with AML in complete remission had lysozyme levels comparable to normal adults, whereas patients with AML in relapse (eight cases) also had abnormally high levels of lysozyme activity. Ten patients with AML in remission and off therapy also had normal lysozyme levels. Three patients with acute lymphatic leukemia had normal lysozyme levels, while one child with monomyelocytic leukemia had substantially elevated lysozyme levels before treatment. It seems that in patients in remission and with normal blood values, the serum lysozyme activity is valuable for monitoring the remission.
对成年急性白血病患者、恶性肿瘤患者以及正常成年人的样本进行了血清溶菌酶活性检测。28例成年急性髓性白血病（AML）患者在诊断时溶菌酶水平显著升高，且所有成年人的溶菌酶水平均不在正常范围内。32例完全缓解的AML患者的溶菌酶水平与正常成年人相当，而复发的AML患者（8例）的溶菌酶活性水平也异常高。10例缓解期且停止治疗的AML患者的溶菌酶水平也正常。3例急性淋巴细胞白血病患者的溶菌酶水平正常，而1例单核细胞白血病患儿在治疗前溶菌酶水平大幅升高。似乎对于缓解期且血液值正常的患者，血清溶菌酶活性对于监测缓解情况具有重要价值。
